Semax (N-Acetyl Semax) is a heptapeptide and synthetic analog of adrenocorticotropic hormone, ACTH 4-10, which was developed in Russia. This peptide has potent nootropic, neuroprotective, neurogenic, and neurorestorative effects, as observed in animal studies. Semax has been extensively researched in mammalian studies involving brain injuries such as stroke, transient ischemic attack, memory and cognitive disorders, optic nerve disease, peptic ulcers, and immune system enhancement. It undergoes an important transformation via N-terminal acetylation to increase stability and biological activity, which has been shown to increase the efficiency of the peptide’s specific mechanism of action.
A 2017 study published in Molecular Genetics and Genomics demonstrated the neuroprotective properties of Semax in rat subjects with ischemic brain trauma. The peptide was observed to enhance the antigen presentation signaling pathway, intensify ischemia’s effect on the interferon signaling pathways, and affect the processes for synthesizing immunoglobulins. Furthermore, the peptide significantly increased expression of the gene encoding the immunoglobulin heavy chain. Researchers postulated that Semax’s neuroprotective mechanism was achieved through “neuroimmune crosstalk” and newly identified properties of Pro-Gly-Pro (PGP).
In addition, further research has indicated that Semax administration can lead to decreased vascular injury and enhanced mRNA neurotrophin synthesis in rats that have suffered cerebral ischemia due to stroke. Semax was also observed to have anti-inflammatory properties, manifesting in reduced levels of vascular endothelial growth factor (VEGFA) in rat study subjects after ischemic brain injury.
In 2007, researchers published a paper in Medical Hypothesis suggesting Semax as a potential future treatment for Attention-Deficit Hyperactivity Disorder (ADHD) and Rett Syndrome. They noted that previous animal studies suggested that Semax was able to augment the effects of psychostimulants on central dopamine release while additionally stimulating central brain-derived neurotrophic factor (BDNF) synthesis. The increased central BDNF activity as a result of Semax administration could prove highly therapeutic in regards to Rett syndrome, while BDNF and increased dopamine release could also highly benefit cases of ADHD.
Semax has demonstrated significant cognitive effects in animal studies that go beyond protection and recovery from acute brain injury. For instance, a study conducted on white rats in 2007 showed that chronic Semax administration had anxiolytic and antidepressant effects, which may be attributed to the activation of the brain serotoninergic system and increased BDNF expression in the hippocampus.
Semax has also been shown to reduce memory and learning deficits in rat subjects treated with amphetamines in utero, leading researchers to conclude that the peptide may aid in neuroprotection and cognitive rehabilitation of prenatal brain damage.
In addition, Semax has demonstrated its potential in treating glaucomatous optic neuropathy by outperforming traditional neuroprotective treatments. Semax has also exhibited neuroprotective properties in animal studies by counteracting the effects of heavy metal poisoning and copper cytotoxicity, and reducing cytotoxicity induced by reduced copper.
Moreover, a clinical study in 2002 found that Semax administration led to healing of peptic ulcers in a significantly higher percentage of patients compared to the control group, providing promising prospects for future therapeutic applications.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION. ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.
All products are produced using lyophilization (freeze-drying), a preservation method that allows peptides to remain fully stable during shipping for approximately 3-4 months. Once a peptide has been reconstituted with bacteriostatic water, it must be refrigerated to maintain integrity. After reconstitution, peptides typically remain stable for up to 30 days when stored properly.
Lyophilization, also referred to as cryodesiccation, is a specialized dehydration process in which peptides are first frozen and then exposed to a low-pressure environment. This causes the water within the vial to transition directly from a solid to a vapor (sublimation), leaving behind a dry, crystalline white material known as a lyophilized peptide. In this powdered form, peptides may be safely stored at room temperature until they are ready to be reconstituted with bacteriostatic water.
After delivery, peptides should be protected from heat and light. If use is expected within the near future (whether days, weeks, or a few months) refrigerated storage below 4°C (39°F) is generally sufficient. Lyophilized peptides are commonly stable at room temperature for several weeks or longer, making short-term ambient storage acceptable when use is anticipated within that timeframe.
For extended storage, ranging from several months to multiple years, freezing is strongly recommended. Storage at -80°C (-112°F) offers optimal long-term stability and helps preserve peptide structure and quality over time.
For more detailed guidance on peptide handling and storage best practices, please refer to the resource below:
Semax is a research-grade synthetic peptide derived from the ACTH(4–10) fragment, engineered for laboratory investigation of neurotrophin signaling, cognitive-performance paradigms, and stress-resilience pathways. In published research contexts, Semax is frequently evaluated in models that track learning, attention, motivation, and neuroprotective biomarker shifts. Each vial is produced to research-grade standards and is intended to support reproducible, protocol-driven experimental design.
In advanced cognitive research frameworks, Semax is often analyzed alongside complementary compounds such as Selank for stress modulation and NAD for cellular energy support. This layered approach allows researchers to isolate performance-driven signaling from recovery or metabolic constraints, improving clarity across experimental outcomes.
Semax Research Peptide Specifications:
| Unit Size | 10 mg/vial |
| Unit Quantity | 1 vial |
| Purity (HPLC) | > 99% |
| Identity | ACTH(4–10) analogue used in neurotrophin and cognitive research |
| Appearance | Lyophilized white powder |
| Source | Chemical synthesis |
| Storage Conditions | Store at ≤ -20°C, protected from light and moisture. Reconstituted solutions may be stored at 2–8°C under controlled laboratory conditions. |
| Research Use Only | Not for human or veterinary use. Intended strictly for laboratory research. |
Semax is widely utilized as a tool compound in neurotrophin-focused research, particularly in studies exploring brain-derived neurotrophic factor (BDNF) expression and plasticity-linked signaling pathways. Its structural foundation allows for interaction with central nervous system signaling cascades associated with learning, memory formation, and adaptive response mechanisms.
Within controlled experimental systems, Semax is often deployed to evaluate correlations between neurochemical signaling and measurable behavioral outcomes. These include task acquisition speed, attention span, and performance stability under stress conditions such as sleep disruption or environmental variability.
Because Semax sits within a broader category of cognitive and neuroregulatory peptides, research protocols frequently incorporate comparative designs. For example, pairing Semax with Selank allows investigators to distinguish between activation-based cognitive effects and anxiety-modulating influences. Similarly, pairing with metabolic compounds such as NAD helps ensure observed outcomes are not limited by cellular energy availability.
Important Research Notice: All products are validated through third-party analytical testing, including HPLC and mass spectrometry. Certificates of Analysis are available for each lot to support traceability and quality assurance.
THIS PRODUCT IS INTENDED FOR LABORATORY RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION.
Semax is commonly incorporated into studies examining neurotrophin activity, particularly BDNF-associated signaling. Researchers evaluate how these pathways influence learning curves, adaptation speed, and memory consolidation in controlled environments.
In behavioral neuroscience, Semax is frequently used to explore attention, motivation, and task performance. These studies require strict environmental controls to reduce variability and maintain reproducibility across cohorts.
Semax is often used in models designed to evaluate how cognitive performance changes under stress or fatigue conditions. When combined with Selank, researchers can better isolate performance activation from stress interference.
Advanced research designs frequently combine Semax with multiple compounds to create layered signaling models. A typical structure may include Semax for cognitive activation, Selank for stress modulation, and NAD for metabolic support. This approach enhances interpretability and reduces confounding variables.
Lyophilized Semax is typically reconstituted in controlled laboratory settings using sterile diluents to achieve a target concentration aligned with the study design. Protocols should standardize preparation, aliquoting, and storage procedures to maintain consistency across experiments.
Minimizing freeze–thaw cycles, protecting solutions from light exposure, and documenting preparation variables are critical steps in ensuring data integrity and reproducibility.
Each production batch undergoes rigorous testing to confirm peptide identity and purity. Analytical methods include high-performance liquid chromatography and mass spectrometry. Documentation is maintained for audit readiness and protocol validation.
Reliable peptide sourcing is a foundational requirement for any serious research program. Laboratories should prioritize suppliers that provide verified analytical documentation, controlled manufacturing processes, and consistent lot-to-lot quality.
Maintaining consistency in sourcing directly impacts data reliability, especially in multi-variable cognitive studies where even minor inconsistencies can skew results.
